Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858256 | 0.88 | CYP1A2 (0.45) | CYP1A2SLC29A1NT5ELMNAPNP | |
| SCHEMBL4370984 | 0.88 | CYP1A2 (0.45) | CYP1A2SLC29A1NT5ELMNAPNP | |
| SCHEMBL4383154 | 0.83 | CYP1A2 (0.41) | CYP1A2SLC29A1NT5ELMNAPNP | |
| SCHEMBL28636803 | 0.83 | DNMT1 (0.42) | CYP1A2SLC29A1NT5ELMNAPNP | |
| SCHEMBL10446997 | 0.80 | PNP (0.64) | LMNAPNPTP53HTTPDE4D | |
| SCHEMBL13833321 | 0.80 | ADORA3 (0.53) | NT5EPNPPDE3AADORA3 | |
| SCHEMBL12031117 | 0.80 | ADORA3 (0.53) | NT5EPNPPDE3AADORA3 | |
| SCHEMBL98907 | 0.80 | ADORA3 (0.53) | NT5EPNPPDE3AADORA3 | |
| SCHEMBL98906 | 0.80 | ADORA3 (0.53) | NT5EPNPPDE3AADORA3 | |
| SCHEMBL18759056 | 0.80 | ADORA3 (0.53) | NT5EPNPPDE3AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009517350-A | — | — | 2009-04-30 | — | — | JP | claimed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | claimed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | claimed |
| US-8119689-B2 | Adjuvants on the basis of bisacyloxypropylcystene conjugates and derivatives and their uses in pharmaceutical compositions | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | CYSLTR2, CYSLTR1, GSTO1 | CYP1A2 3367/4885SLC29A1 2407/4885NT5E 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.